Zimmer Biomet Holdings is currently trading at a significant valuation discount, around 10 times forward earnings, despite showing strong financial performance. The company reported a 9.3% increase in net sales, a 15.5% rise in adjusted earnings per share, and an improved gross margin of 73.0%. Its strong position in orthopedic implants, reliable cash generation, manageable debt, and ongoing share buybacks support steady earnings, though the market views it as a slow-growth stock. This valuation reflects investor caution despite the company's robust fundamentals.
Zimmer Biomet has appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai brings nearly 30 years of leadership experience in the medical technology sector, including senior roles at Alcon and GE Healthcare. He re...
Zimmer Biomet Holdings announced its second quarter 2026 earnings conference call will be held on August 5 at 8:30 a.m. ET, with a news release detailing results available earlier that day. The call will be webcast live and available for replay on th...
